Mirvetuximab soravtansine

Drug Profile

Mirvetuximab soravtansine

Alternative Names: Anti-FOLR1-monoclonal-antibody-maytansinoid-conjugate-IMGN-853; IMGN-853; M9346A-sSPDB-DM4; M9346A-sulfo-SPDB-DM4

Latest Information Update: 18 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator ImmunoGen
  • Developer ImmunoGen; National Comprehensive Cancer Network
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Maytansinoids; Monoclonal antibodies
  • Mechanism of Action Folate receptor 1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Phase II Breast cancer
  • Phase I/II Endometrial cancer
  • Phase I Solid tumours

Most Recent Events

  • 05 Jun 2017 Phase-II clinical trials in Breast cancer (Monotherapy, Newly diagnosed, Second-line therapy or greater, Metastatic disease) in USA (IV) (NCT03106077)
  • 02 Jun 2017 Additional efficacy data from a phase I trial in Ovarian cancer presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 02 Jun 2017 Adverse events data from the phase Ib FORWARD II trial in Ovarian cancer, Peritoneal cancer and Fallopian tube cancer, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top